{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:36Z","timestamp":1788675456796,"version":"build-2803163510"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,21]]},"DOI":"10.7759\/cureus.109334","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:22:08Z","timestamp":1779358928000},"source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy-Induced Glutamic Acid Decarboxylase 65 Cerebellitis"],"prefix":"10.7759","author":[{"given":"Alysse","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"National Cancer Institute. immune checkpoint inhibitors. (2022). Accessed: November 22, 2025: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy\/checkpoint-inhibitors.."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman AD","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020, 20:651-68. 10.1038\/s41577-020-0306-5","journal-title":"Nat Rev Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon AC","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK, et al.. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021, 9:e002890. 10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco R","year":"2021","unstructured":"Velasco R, Villagr\u00e1n M, Jov\u00e9 M, et al.. Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol. 2021, 78:864-73. 10.1001\/jamaneurol.2021.0249","journal-title":"JAMA Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae186","article-title":"Immune-related encephalitis after immune checkpoint inhibitor therapy","volume":"30","author":"Buckley MW","year":"2025","unstructured":"Buckley MW, Balaji Warner A, Brahmer J, et al.. Immune-related encephalitis after immune checkpoint inhibitor therapy. Oncologist. 2025, 30:oyae186. 10.1093\/oncolo\/oyae186","journal-title":"Oncologist"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.97372","article-title":"Acute cerebellitis due to administration of durvalumab for recurrent endometrial cancer: a case report","volume":"17","author":"Kawahara H","year":"2025","unstructured":"Kawahara H, Taketoshi K, Nagano T, Matsuo T, Kobayashi H. Acute cerebellitis due to administration of durvalumab for recurrent endometrial cancer: a case report. Cureus. 2025, 17:e97372. 10.7759\/cureus.97372","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/480645-immunotherapy-induced-glutamic-acid-decarboxylase-65-cerebellitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:22:08Z","timestamp":1779358928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/480645-immunotherapy-induced-glutamic-acid-decarboxylase-65-cerebellitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.109334","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}